Transcription of HIGHLIGHTS OF PRESCRIBING INFORMATION …
{{id}} {{{paragraph}}}
US-21559. HIGHLIGHTS OF PRESCRIBING INFORMATION Clostridium difficile-Associated Diarrhea: PPI therapy may be associated with These HIGHLIGHTS do not include all the INFORMATION needed to use NEXIUM safely and increased risk. ( ). effectively. See full PRESCRIBING INFORMATION for NEXIUM. Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist or spine. ( ). NEXIUM (esomeprazole magnesium) delayed-release capsules, for oral use Cutaneous and Systemic Lupus Erythematosus: Mostly cutaneous; new onset or NEXIUM (esomeprazole magnesium) for delayed-release oral suspension exacerbation of existing disease; discontinue NEXIUM and refer to specialist for Initial Approval: 1989 (omeprazole) evaluation.
HIGHLIGHTS OF PRESCRIBING INFORMATION. These highlights do not include all the information needed to use NEXIUM safely and effectively. See full prescribing information for NEXIUM.
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}